UPDATE 1-Antigenics up as Glaxo vaccine trials use co’s adjuvant

* Glaxo starts last-stage trials for shingles vaccine

* Antigenics Shares up 20 pct

Aug 25 (BestGrowthStock) – Antigenics Inc (AGEN.O: ) said its vaccine
adjuvant was a key component in GlaxoSmithKline Plc’s (GSK.L: )
experimental shingles vaccine that started final stage trials
recently, sending the U.S. biotechnology company’s shares up as
much as 20 percent.

Glaxo plans to study more than 30,000 patients globally for
shingles, a viral disease that results in painful rash on one
side of the body with limited current treatment options.

An adjuvant helps boost the immune system response,
requiring less quantity of vaccine in each dose.

Antigenics’ experimental adjuvant QS-21 is being tested in
nearly 20 indications, including Johnson & Johnson’s (JNJ.N: )
potential treatment for Alzheimer’s disease.

“This adjuvant has substantial revenue potential for
Antigenics with no associated developments costs to the
company,” Antigenics’ Chief Executive Garo Armen said in a

The Lexington, Massachusetts-based company’s shares, which
have lost 63 percent of their value over the past one year,
were up 10 percent at 85 cents in late afternoon trade
Wednesday on Nasdaq. They touched a high of 94 cents earlier in
the session.

More than 2.5 million shares were traded by 1547 ET, nearly
10 times their 10-day average volume.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by
Vinu Pilakkott)

UPDATE 1-Antigenics up as Glaxo vaccine trials use co’s adjuvant